Signals Blog
Menu

Cell Therapy Deal Review: August

. Welcome to your cell therapy deal review for the month of August. Synthetic biology giant Intrexon closed a large financing; Immune Design announced a collaboration to pair its viral-based immunotherapy platform with a checkpoint inhibitor; and, NantKwest received a...

Update from the Clinic: August

. Welcome to your Update from the Clinic for the month of August. The adult stem cell community enjoyed a much needed confidence boost after TiGenix announced its Phase 3 trial hit its primary endpoint. Northwest confirmed its Phase 3 trial of DCVax in glioblastoma is...

Right Turn: The why and what of clinical trials

. Not quite daily, but often enough to have a prepared message at the ready, I get inquiries from people seeking a stem cell treatment for themselves or loved ones who suffer from one disease/condition or another. (When I’m not working on Signals, I am responsible for...

The tiny fingers that touch stem cells

. I was reading Nature the other day and came across a neat article from Yukikio Yamashita’s group at the University of Michigan entitled Nanotubes mediate niche–stem-cell signalling in the Drosophila testis. It may not sound interesting to our average reader, but the...